Company intelligence / Profile preview

Quoin Pharmaceuticals Ltd.

Ownership: Public · QNRX
Development stage: Phase 2

Overview

Quoin's lead product QRX003 has shown positive results in pediatric Netherton Syndrome studies, with one patient showing transformational improvement after just two weeks of whole-body application, including clear visual evidence of skin healing and discontinuation of previously required medications. The company is targeting FDA approval for its lead asset in 2026.

Therapeutic areas: Rare DiseasesDermatologyCardiovascularRheumatology
Modalities: Topical formulationsNovel drug delivery systems
Industry: Biotech

Drug pipeline

11 assets

QRX003

10 more assets in the full pipeline.

Request access →

Partnerships

Marketing and distribution partnerships spanning 60 countries including Canada, Australia, New Zealand, the Middle East, China, Hong Kong, Taiwan, Central and Eastern Europe, the Baltic States, and several countries in Latin America

Financials

Market cap: $13.9M
Total revenue: $0
Enterprise value: $3.1M

Beyond the preview

Go deeper on Quoin Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quoin Pharmaceuticals Ltd..

Explore the full profile